MARKET

RGNX

RGNX

Regenxbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.46
-0.62
-1.87%
Pre Market: 32.46 0 0.00% 08:18 05/06 EDT
OPEN
32.79
PREV CLOSE
33.08
HIGH
34.07
LOW
32.01
VOLUME
23
TURNOVER
--
52 WEEK HIGH
50.26
52 WEEK LOW
25.93
MARKET CAP
1.38B
P/E (TTM)
-10.8388
1D
5D
1M
3M
1Y
5Y
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -6.19% and -32.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 12h ago
Regenxbio Q1 EPS $(1.20) Beats $(1.28) Estimate, Sales $18.90M Miss $23.23M Estimate
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1.28) by 6.25 percent. This is a 11.11 percent decrease over losses of $(1.08) per share from the same
Benzinga · 15h ago
Regenxbio EPS beats by $0.02, misses on revenue
Regenxbio (RGNX): Q1 GAAP EPS of -$1.20 beats by $0.02.Revenue of $18.9M (+7.1% Y/Y) misses by $4.34M.Financial Guidance: Based on its current operating plan, REGENXBIO expects its balance in cash, cash
Seekingalpha · 16h ago
REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights
, /PRNewswire/ --
PR Newswire - PRF · 16h ago
REGENXBIO, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 5, 2021 / REGENXBIO, Inc. (NASDAQ:RGNX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 18h ago
-- Earnings Flash (RGNX) REGENXBIO Reports Q1 Loss $-1.20
MT Newswires · 20h ago
-- Earnings Flash (RGNX) REGENXBIO Reports Q1 Revenue $18.9M
MT Newswires · 20h ago
Earnings Scheduled For May 5, 2021
  Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
Benzinga · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RGNX. Analyze the recent business situations of Regenxbio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RGNX stock price target is 64.63 with a high estimate of 100.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 268
Institutional Holdings: 28.74M
% Owned: 67.62%
Shares Outstanding: 42.51M
TypeInstitutionsShares
Increased
49
2.07M
New
39
495.81K
Decreased
63
2.92M
Sold Out
18
829.06K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Director
Allan Fox
President/Chief Executive Officer/Executive Director
Kenneth Mills
Chief Financial Officer/Senior Vice President
Vittal Vasista
Senior Vice President/Chief Technology Officer
Curran Simpson
Senior Vice President/Chief Scientific Officer
Olivier Danos
Senior Vice President
Steve Pakola
Lead Director/Independent Director
A. N. Karabelas
Independent Director
Daniel Abdun-Nabi
Independent Director
Luke Beshar
Independent Director
Alexandra Glucksmann
Independent Director
David Stump
Independent Director
A.N. Karabelas
Independent Director
Daniel Tasse
No Data
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Webull offers kinds of Regenxbio Inc stock information, including NASDAQ:RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.